



OncoMethylome Sciences Signs Agreement for the Potential use of its technology platform in GlaxoSmithKline Biologicals Immunotherapy Development Program

DURHAM, the United States, and LIEGE, BELGIUM – September 23rd, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.

OncoMethylome's biomarker is stable, highly accurate, and, unlike many other biomarkers, allows for the analysis of non-invasive tissue samples.

"We are very pleased to enter into this agreement with GSK. This project was initiated in 2007 and is a prime example of how we can bring our considerable regional strengths to bear on global healthcare issues," said Jan Groen, Ph.D., Chief Executive Officer of OncoMethylome. "Furthermore, this agreement marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK, and underpins our strategy of leveraging our methylation specific PCR platform in the rapidly emerging field of companion diagnostics and personalized medicine."

About OncoMethylome Sciences

OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops tests to assist physicians in detecting and treating cancer. The company's tests are based on proprietary gene methylation technology and are designed to help the physician accurately detect early stages of cancer, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono and Qiagen.

For more information:

Dr. Jan Groen

CEO

Telephone (+32) 4.364.20.70

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. OncoMethylome expressly disclaims any obligation to update any such

forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.